semaglutide eli lilly Novo, weight-loss drugs should be first option obesity treatments, European doctors say Novo Nordisk's 'Semaglutide' gains weight

Hims & Hers later pulled the oral compounded medication from its platform following legal threats from Novo and scrutiny from federal regulators.

Clinical evidence The SURMOUNT-1 trial found that participants without diabetes lost an average of 22.5% of body weight at the 15 mg dose after 72 weeks

Her HbA1c was 6% and her fasting glucose was 5.3 mmol/l

How GLP-1 Weight-Loss Medications Can Help GLP-1 medications such as semaglutide and tirzepatide may support weight loss by helping with appetite regulation, cravings, insulin resistance, and blood-sugar control

Unaddressed weight and metabolic dysfunction drive a cascade of downstream consequences cardiovascular disease, fatty-liver disease, kidney damage, neuropathy, and shortened lifespan

To enter, sign up for our newsletter or book an appointment Your Healt